Details of the Drug

General Information of Drug (ID: DMXR287)

Drug Name
FR-79620
Synonyms 3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Preclinical [1]
Eating disorder 6B82 Preclinical [1]
Obesity 5B81 Preclinical [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 235.28
Logarithm of the Partition Coefficient (xlogp) 2.7
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C15H13N3
IUPAC Name
3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine
Canonical SMILES
CC1=C(N=C(N1)C2=CC=CC=C2)C3=CN=CC=C3
InChI
InChI=1S/C15H13N3/c1-11-14(13-8-5-9-16-10-13)18-15(17-11)12-6-3-2-4-7-12/h2-10H,1H3,(H,17,18)
InChIKey
CAQAIFUDUGDPFB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
10421577
TTD ID
D02NMO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuropeptide Y receptor type 5 (NPY5R) TTY6EWA NPY5R_HUMAN Antagonist [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Neuropeptide Y receptor type 5 (NPY5R) DTT NPY5R 7.49E-01 1.19E-02 0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.